An Observational Study, Called DEAR, to Learn More About Treatment With Darolutamide, Enzalutamide and Apalutamide in Men With Non-metastatic Castration-resistant Prostate Cancer in Real World Settings
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Bayer
Age
18–any
Sex
MALE
Healthy volunteers
Not accepted
You may be eligible if
Men diagnosed with prostate cancer
Diagnosis of castration-resistant prostate cancer (CRPC) prior to or during the patient identification period
Treatment with daro, enza, or apa initiated for the first time during the patient identification period for nmCRPC
Age ≥ 18 years at index date
At least 6 months of electronic medical records (EMR) activity after the index date unless the patient died earlier than 6 months
You may not be if
Evidence of metastatic disease before or 30 days after index date.
Prior history (within five years before index date) of other primary cancers, except for non-melanoma skin cancer
Patients with multiple SGARIs recorded at index date
Use of a NAH agent (daro, enza, apa or abiraterone acetate) prior to the index date
Evidence of inclusion in clinical trials during the study period.
Clareo Health | An Observational Study, Called DEAR, to Learn More About Treatment With Darolutamide, Enzalutamide and Apalutamide in Men With Non-metastatic Castration-resistant Prostate Cancer in Real World Settings
